Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
2024年5月6日 - 5:25PM
Curium Announces First Commercial Doses in Germany of PYLCLARI® –
An Innovative 18F-PSMA PET Tracer Indicated in Patients With
Prostate Cancer
Curium, a world leader in nuclear medicine, announced that today in
Munich and Nurnberg, Germany the first commercial doses of
PYLCLARI
® have been delivered.
PYLCLARI
® (INN: Piflufolastat (18F) also known as
(18F)-DCFPyL), is indicated for the detection of prostate-specific
membrane antigen (PSMA) positive lesions with positron emission
tomography (PET) in patients with prostate cancer in the following
clinical settings:
- Primary staging of patients with high-risk prostate cancer
prior to initial curative therapy
- To localize recurrence of prostate cancer in patients with a
suspected recurrence based on increasing serum prostate-specific
antigen (PSA) levels after primary treatment with curative
intent
Benoit Woessmer, PET Europe CEO at Curium
commented, “We are pleased with the growing availability
of PYLCLARI® to more nuclear medicine physicians
and their patients across Europe. With today’s announcement, we are
extremely proud to be improving the choice of diagnostic modalities
available to our customers in Germany – ultimately for the benefit
of patients with prostate cancer.”
In Germany, prostate cancer is the most common cancer among men
with around 63,400 new cases diagnosed nationwide every year.
Today’s announcement is part of the continued roll-out of
PYLCLARI® across the European Union, which is now
available for patients with prostate cancer in Greece, Italy, and
the Netherlands.
For more information about PYLCLARI®:
www.pylclari.com
In the U.S., Lantheus received approval for PYLARIFY®
(Piflufolastat (18F) Injection) from the Food and Drug
Administration (FDA) in May 2021. It is the #1 utilized PSMA PET
agent in the U.S. market. The European rights were licensed by
Curium from Progenics, a Lantheus company, in 2018.
About Curium
Curium is a world leader in nuclear medicine. We develop,
manufacture, and distribute world-class radiopharmaceutical
products to help patients around the globe. Our proven heritage
combined with a pioneering approach are the hallmarks to deliver
innovation, excellence, and unparalleled service.
With manufacturing facilities across Europe and the United
States, Curium delivers SPECT, PET and therapeutic
radiopharmaceutical solutions for life-threatening diseases to over
14 million patients annually. The name ‘Curium’ honors the legacy
of pioneering radioactive materials researchers Marie and Pierre
Curie, after whom the radioactive element curium was named and
emphasizes our focus on nuclear medicine. To learn more, visit
www.curiumpharma.com
For more information:Ross Bethell, VP, Head of
Global
CommunicationsCuriumcommunications@curiumpharma.com